SCYNEXIS, Inc. SCYX
2.61 USD -0.21 (-7.62%)
Regular-session close
2.57 -0.04 -1.34%
After hours · Nov 19, 4:23 PM ET
2.51 Day range 2.88
2.61 52-week range 8.88
- YTD
- -48.52%
- 1 year
- -44.81%
News
benzinga.com SCYNEXIS Q3 EPS $(0.71) Beats $(0.72) Estimate SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.72) by 1.39 percent. This is a 47.79 percent increase over losses of $(1.36) per…
globenewswire.com SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update JERSEY CITY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions…
globenewswire.com SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today…benzinga.com SCYNEXIS Announces Its Phase 1 Trial Of Intravenous Formulation Of SCY-247 To Treat Invasive Fungal Infections Showed Intravenous Doses Of 50 Mg Or Higher Achieved Exposures At Or Above Target Identified In Murine Models Of Invasive Candidiasis SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS", or the "Company"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline…
globenewswire.com SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions…
globenewswire.com SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions…
defenseworld.net SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.93 and traded as high as $5.29.…
globenewswire.com SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated
defenseworld.net Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX) Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies…
globenewswire.com SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions…
defenseworld.net Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial Survey Adherex Technologies (NASDAQ: FENC - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the…
globenewswire.com SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D. JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions…
globenewswire.com SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for…
globenewswire.com SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished…
defenseworld.net SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average – Here’s What Happened SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.78 and traded as high as $5.35.…
globenewswire.com SCYNEXIS to Participate in Upcoming Investor Conferences JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and…
globenewswire.com SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat…
defenseworld.net SCYNEXIS (NASDAQ:SCYX) Shares Cross Below 200 Day Moving Average – Time to Sell? SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $5.89 and traded as…
globenewswire.com SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced…
globenewswire.com SCYNEXIS Announces One-for-Eight Reverse Stock Split SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026
globenewswire.com SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today…
globenewswire.com SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) JERSEY CITY, N. J. , May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address…
